← Leaderboards
Kenneth W Narducy
St. Charles Pharmaceuticals
$2,281,698
Attributed
$2,281,698
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,281,698 · 7
By mechanism
R44$1,370,791 · 2
R42$499,068 · 1
R43$311,839 · 3
R41$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at St. Charles Pharmaceuticals
Same institution · by research overlap
- Kenneth Wayne Narducy$1,061,192
- Anthony L Vaccarino$562,081
Others in their field
Top investigators on “Acetaminophen”
- William M Lee · University Of Texas Sw Med Ctr/Dallas$24,215,692
- Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
- Laura P James · University Of Arkansas Med Scis Ltl Rock$9,639,468
- Susan J Sumner · Research Triangle Institute$8,875,336
- Rebecca Gersnoviez Clifton · George Washington University$8,736,580
- Ronald K Ross · University Of Southern California$8,365,947
Research focus
AcetaminophenAnalgesicsPainDrug Design /Synthesis /ProductionLaboratory MouseDrug Adverse EffectAntipyreticHepatotoxinPharmacokineticsAnalgesiaAge DifferenceAnalogLaboratory RatSweetening AgentsImmature AnimalDrug Screening /EvaluationAnimal Old AgeGlutathioneAcuteFormalinFundingHepatotoxicityCarbonDogs
Grant awards (9)
Novel drug combinations for the management of pain$535,671
R44 · FY2007 · NS · contact PI
Development of Non-Narcotic Intravenous Analgesics$111,893
R43 · FY2007 · NS · contact PI
Development of SCP-1 to Treat Pain in the Elderly$271,014
R42 · FY2004 · AG
Development of Novel Therapeutics for Postsurgical Pain$399,780
R44 · FY2003 · NS
Development of SCP-1 to Treat Pain in the Elderly$228,054
R42 · FY2003 · AG
Development of SCP-1/opioid combinations for pain$99,947
R43 · FY2003 · NS
Development of Novel Therapeutics for Postsurgical Pain$435,340
R44 · FY2002 · NS
ANALGESICS FOR CHRONIC PAIN TREATMENT IN THE ELDERLY$100,000
R41 · FY2001 · AG
DEVELOPMENT OF ANALGESICS WITH FEWER SIDE EFFECTS$99,999
R43 · FY2000 · NS